Last Updated: November 16, 2026

Details for Patent: 10,933,046

« Back to Dashboard


Which drugs does patent 10,933,046 protect, and when does it expire?

Patent 10,933,046 protects EPSOLAY and is included in one NDA.

This patent has twelve patent family members in two countries.

Summary for Patent: 10,933,046
Title:Method for treatment of rosacea in patients aged 65 years and older
Abstract:A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.
Inventor(s):Ofer Toledano, Ofra Levy-Hacham, Ori NOV, Vered RAM
Assignee: Mayne Pharma LLC
Application Number:US16/794,839
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;
Patent landscape, scope, and claims:

US Patent 10,933,046: Benzoyl Peroxide Rosacea Regimen, Claim Scope and Patent Landscape

US Patent 10,933,046 protects a narrow clinical-use regimen for treating rosacea with once-daily, encapsulated or microencapsulated benzoyl peroxide in patients aged 65 years and older. The claims are directed primarily to treatment outcomes, not merely to the composition. The strongest commercial relevance is to 5% benzoyl peroxide products such as Epsolay, while ordinary benzoyl peroxide acne products generally fall outside the claims unless they satisfy every patient, formulation, dosing, and efficacy limitation.

The patent is commercially significant because it combines four limitations that are difficult to establish from product labeling alone: an elderly patient population, rosacea treatment, a single active ingredient, and specified clinical outcomes against vehicle control.

What does US Patent 10,933,046 protect?

The patent protects methods and compositions involving:

Claim element Requirement
Disease Rosacea, including erythematotelangiectatic, papulopustular, phymatous or ocular rosacea
Patient population Subjects aged 65 years and older
Active ingredient Benzoyl peroxide as the only active ingredient
Concentration About 2.5% to about 10% w/w, with dependent claims directed to approximately 5%
Delivery Topical application
Formulation Encapsulated or microencapsulated benzoyl peroxide
Dosing Once daily
Duration At least 2, 4, 8 or 12 weeks, depending on the claim
Vehicle Pharmaceutically acceptable carrier or excipient
Clinical result Prescribed IGA success rate or reduction in inflammatory lesions
Concomitant treatment Benzoyl peroxide must be the sole active ingredient administered during the regimen

The patent therefore does not broadly cover every topical benzoyl peroxide formulation or every rosacea treatment. It covers a defined therapeutic protocol tied to a defined patient subgroup and specified results.

How are the claims organized?

Claims 1 through 12: IGA success-rate regimen

Independent claim 1 requires treatment for at least two weeks and an IGA success rate of at least 15% in the treated group. The claim also requires encapsulation or microencapsulation and limits the formulation to benzoyl peroxide as the only active ingredient.

The dependent claims create a time-and-response ladder:

Claim Treatment period Required IGA success rate Vehicle-control comparison
1 At least 2 weeks At least 15% Not required
2 At least 2 weeks At least 15% At least 10% greater than vehicle
3 At least 4 weeks At least 25% Not required
4 At least 4 weeks At least 25% At least 2% greater than vehicle
5 At least 8 weeks At least 45% Not required
6 At least 8 weeks At least 45% At least 27% greater than vehicle
7 At least 12 weeks At least 50% Not required
8 At least 12 weeks At least 50% At least 28% greater than vehicle

Claims 9 through 12 add a 5% concentration, first-line treatment, cream or emulsion dosage forms, and extended-release formulations.

Claims 13 and 14: severe rosacea composition-for-use claims

Claims 13 and 14 use a pharmaceutical-composition-for-use format and address severe rosacea in patients aged 65 years and older. Claim 13 incorporates the four treatment durations and corresponding IGA thresholds:

  • At least 15% after at least two weeks;
  • At least 25% after at least four weeks;
  • At least 45% after at least eight weeks; and
  • At least 50% after at least 12 weeks.

Claim 14 narrows the composition to approximately 5% benzoyl peroxide.

Claims 15 through 25: inflammatory-lesion reduction

Claims 15 through 25 protect a second efficacy pathway based on the mean percentage decrease in inflammatory lesions from baseline.

Treatment period Benzoyl peroxide reduction Vehicle reduction
At least 2 weeks About 40% About 25%
At least 4 weeks About 55% About 35%
At least 8 weeks About 60% About 35%
At least 12 weeks About 65% About 35%

Claim 24 adds a second set of values, including approximately 45%, 60%, 69% and 70% reductions for the four treatment periods, compared with vehicle reductions of approximately 29%, 42%, 41% and 41%.

The lesion-reduction claims may be important in enforcement because they do not depend exclusively on IGA status. A product can potentially satisfy the claims through documented inflammatory-lesion outcomes even if the sponsor does not characterize its commercial endpoint in the same terms.

What is the core infringement test under US Patent 10,933,046?

A potentially infringing product or regimen must satisfy every limitation of an asserted claim. For the principal independent claims, the relevant questions are:

  1. Is the patient at least 65 years old?
  2. Is the condition rosacea?
  3. Is benzoyl peroxide the only active ingredient?
  4. Is the concentration approximately 2.5% to 10% w/w?
  5. Is the benzoyl peroxide encapsulated or microencapsulated?
  6. Is the product applied topically once daily?
  7. Is the treatment continued for the claimed period?
  8. Does the treated group achieve the claimed IGA or inflammatory-lesion result?
  9. Is benzoyl peroxide the sole active ingredient administered during the regimen?

A generic or follow-on sponsor would not ordinarily be exposed merely because it markets a 5% benzoyl peroxide cream. The exposure increases if the product is positioned for rosacea, uses an encapsulated delivery system, and relies on the same once-daily clinical protocol.

The “sole active ingredient administered” limitation is narrower than a conventional “only active ingredient in the composition” limitation. It can implicate concomitant therapies used during a clinical trial or commercial treatment course. A sponsor that instructs patients to use metronidazole, ivermectin, azelaic acid or another active rosacea therapy may argue that the regimen does not meet the claimed monotherapy requirement. That argument depends on the prescribing instructions, clinical protocol, product labeling and actual use evidence.

How strong are the patent claims?

Strengths

The claims have several features that can create meaningful enforcement leverage:

  • They are directed to a specific age group rather than the entire rosacea market.
  • They require a controlled-release or encapsulated benzoyl peroxide technology.
  • They recite concrete clinical outcomes.
  • The claims cover both IGA success and inflammatory-lesion reduction.
  • The 5% dependent claims align with the concentration used in the leading commercial product, Epsolay.
  • The claims cover multiple treatment durations, reducing the importance of a short-term clinical-performance dispute.

The formulation and age limitations also make a simple anticipation reference less likely. A prior-art document may disclose benzoyl peroxide for rosacea, but it must disclose the claimed concentration, delivery system, elderly population, dosing schedule and outcome limitations in the required combination.

Vulnerabilities

The claims also present litigation and validity risks.

First, benzoyl peroxide was widely known for dermatological use before the patent family’s filing. Prior art concerning benzoyl peroxide for acne, rosacea, follicular disease or inflammatory skin conditions could support an obviousness challenge when combined with known topical delivery technologies.

Second, the result limitations may invite written-description and enablement challenges. The patent must adequately support the claimed clinical outcomes across the full concentration range of approximately 2.5% to 10%, the full elderly population, the specified rosacea subtypes, and the claimed treatment durations.

Third, the claims use “about” for concentrations and clinical percentages. That language provides flexibility but creates construction disputes over the permitted numerical range.

Fourth, the claims refer to an “investor global assessment” scale. In dermatology, the standard term is generally “Investigator’s Global Assessment.” The apparent terminology issue may create an interpretation dispute, although courts commonly construe an obvious drafting error in light of the specification and prosecution history.

Fifth, claims 13 and 23 refer to severe rosacea, while the principal regimen claims do not expressly require severe disease. This difference affects both validity and infringement analysis. The broader claims may face more prior-art exposure; the severe-rosacea claims may be narrower but easier to map to a labeled indication if the product is approved for moderate-to-severe disease.

What formulation technology is protected?

The claims require that benzoyl peroxide be “encapsulated or microencapsulated.” This is a material limitation. A conventional non-encapsulated benzoyl peroxide cream would generally not satisfy the literal formulation requirement.

The patent does not, based on the supplied claims, require a particular:

  • Capsule polymer;
  • Particle size;
  • Release profile;
  • Encapsulation efficiency;
  • Manufacturing process;
  • Emulsion type;
  • Preservative system; or
  • Excipient combination.

Claims 11 and 21 expressly identify creams and emulsions. Claims 12 and 22 identify extended-release formulations. The independent claims, however, do not appear limited to a cream, emulsion or specific release mechanism. A non-cream encapsulated formulation could therefore remain within the independent claim scope if all other limitations are satisfied.

The formulation limitation is likely linked to the commercial differentiation of Epsolay. Epsolay is a 5% benzoyl peroxide cream approved by the FDA for the treatment of inflammatory lesions of rosacea in adults. Its delivery technology is designed to improve tolerability relative to conventional benzoyl peroxide products. The product label identifies benzoyl peroxide as the active ingredient and instructs once-daily application.[1]

What is the FDA and Orange Book status?

The FDA approved Epsolay, a 5% benzoyl peroxide cream, for the treatment of inflammatory lesions of rosacea in adults in April 2022. The product is associated with Galderma Laboratories, L.P., while the underlying formulation and patent estate originated with Sol-Gel Technologies Ltd. or related entities.[1][2]

The relevant regulatory distinction is important:

  • FDA approval covers the labeled indication and dosing instructions.
  • The patent claims cover a narrower or differently framed population and clinical-use regimen.
  • The label does not, by itself, establish that every patented efficacy threshold is met.
  • Orange Book listing, if applicable to the approved product and patent, affects generic certification and litigation timing, but it does not expand the patent’s claim scope.

A patent directed to a method of use may be listed in the Orange Book when it claims an approved method of using the drug product. Composition and formulation patents may also be listed when they claim the approved product. Orange Book status should therefore be assessed by patent number, expiration date, use code and the specific NDA listing rather than by the presence of the patent in a broader patent family.[3]

The supplied claim set does not establish the current Orange Book listing status, use code or any terminal-disclaimer adjustment for US 10,933,046. Those items are regulatory-record facts rather than matters that can be determined from the claims alone.

When does US Patent 10,933,046 lose exclusivity?

The patent was granted in 2022. Its enforceable term is governed by the earliest effective nonprovisional filing date in the family, subject to patent-term adjustment, patent-term extension and any terminal disclaimer. A reliable expiration date cannot be calculated from the claims provided.

For commercial planning, the patent should be treated as a later-expiring use or formulation asset in the Epsolay estate rather than as the sole exclusivity right. FDA exclusivity and other related patents may create separate barriers. The controlling dates are:

Exclusivity component Relevance
US 10,933,046 patent term Protects the claimed elderly-patient regimen and outcomes
Related formulation patents May protect encapsulation, particle structure or composition
Method-of-use patents May protect rosacea indications or dosing
FDA regulatory exclusivity May delay certain abbreviated approvals independently of patent term
Orange Book listing Determines Paragraph IV certification and potential 30-month stay mechanics
Patent-term adjustment or extension May move the effective expiration date

A generic applicant must evaluate the full patent family and FDA listing, not just US 10,933,046.

Which companies could challenge the patent?

Potential challengers include:

  • Generic dermatology companies seeking to market benzoyl peroxide products;
  • Manufacturers of non-encapsulated 5% benzoyl peroxide creams;
  • Developers of alternative encapsulation systems;
  • Companies seeking a rosacea indication for an existing benzoyl peroxide product; and
  • 505(b)(2) applicants using a different formulation or dosing protocol.

A Paragraph IV challenge would likely focus on anticipation, obviousness, written description, enablement, indefiniteness and non-infringement. The strongest non-infringement position would involve a formulation that is not encapsulated or microencapsulated, a concentration outside the claimed range, or a label that does not direct treatment of rosacea in patients aged 65 years and older.

The strongest invalidity theories would likely combine:

  • Prior art disclosing benzoyl peroxide for inflammatory dermatological disease;
  • Prior art disclosing encapsulated or controlled-release benzoyl peroxide;
  • Rosacea treatment literature;
  • Clinical data involving elderly subjects; and
  • General knowledge concerning once-daily topical dosing.

A generic label that omits the patented elderly population may reduce induced-infringement risk, but it does not eliminate all exposure. Actual prescribing, promotional materials and physician instructions can become relevant in a litigation record.

What litigation and settlement risks exist?

A Paragraph IV filing against an Orange Book-listed product could trigger patent litigation under the Hatch-Waxman Act and a potential 30-month stay of FDA approval, subject to statutory exceptions and listing-specific facts.[4] The settlement outcome would depend on the patent family, the challenged claims and the proposed generic label.

Potential settlement structures include:

  • A license with a fixed generic launch date;
  • A launch date tied to patent expiration;
  • A no-contest or contingent license arrangement;
  • Carve-out labeling that excludes rosacea use;
  • A formulation redesign that removes encapsulation; or
  • A covenant not to sue limited to non-rosacea uses.

The claims’ elderly-population limitation may support a negotiated carve-out if the generic sponsor can market benzoyl peroxide for acne or other dermatological indications without directing use for rosacea in patients aged 65 and older.

No litigation or settlement can be attributed to US 10,933,046 from the claim text alone. Patent litigation status must be confirmed through PACER, district-court dockets, the Federal Circuit docket and FDA Paragraph IV records.

How does Epsolay compare with conventional benzoyl peroxide products?

Issue Epsolay-type product Conventional benzoyl peroxide product
Active ingredient 5% benzoyl peroxide Commonly 2.5%, 5% or 10%
Delivery Encapsulated or controlled-release technology Often unencapsulated
Primary market Rosacea Acne
Dosing Once daily Product-specific
Patent exposure High if used for elderly rosacea patients Lower unless encapsulated and promoted for rosacea
FDA indication Rosacea for Epsolay Usually acne or cosmetic/OTC use
Claim risk Depends on patient age, indication and outcomes Often fails one or more claim limitations

The patent estate is strongest against a directly substitutable 5% encapsulated product marketed for rosacea. It is weaker against an unencapsulated acne product or a product whose label excludes rosacea treatment.

What generic launch scenarios are most plausible?

Scenario 1: Same 5% encapsulated formulation

This presents the highest risk. A generic would need to address the formulation claims, method claims and any related patents. A Paragraph IV litigation strategy would be likely if the commercial opportunity is large enough.

Scenario 2: Non-encapsulated 5% formulation

This may avoid literal infringement of the claims requiring encapsulation or microencapsulation. The sponsor would still need to address any separate patents covering benzoyl peroxide concentration, rosacea treatment or formulation components.

Scenario 3: Rosacea label excluding patients aged 65 years and older

This could reduce literal infringement risk under the supplied claims. It may not be commercially attractive if the product’s principal target population includes older adults.

Scenario 4: Alternative active ingredient

Metronidazole, ivermectin and azelaic acid products would generally fall outside these benzoyl peroxide claims. They may face separate patent, regulatory or exclusivity barriers.

Key Takeaways

  • US 10,933,046 is a clinical-use and composition-for-use patent centered on encapsulated or microencapsulated benzoyl peroxide for rosacea in patients aged 65 years and older.
  • The claims require benzoyl peroxide to be the sole active ingredient administered during treatment.
  • The key commercial concentration is approximately 5% benzoyl peroxide.
  • The patent protects both IGA success rates and reductions in inflammatory lesions.
  • A conventional, non-encapsulated benzoyl peroxide acne product generally would not satisfy the supplied claims.
  • Epsolay is the principal commercial product aligned with the patent’s formulation and dosing profile.
  • The most important validity issues are obviousness, enablement, written description, indefiniteness and the interpretation of clinical-result limitations.
  • Orange Book status, patent-term adjustment, related-family patents and litigation records must be assessed separately from the claim language.
  • A generic sponsor has the clearest design-around path through a non-encapsulated formulation, a non-rosacea label or a regimen that does not direct treatment in patients aged 65 years and older.

FAQs

Does US 10,933,046 cover all 5% benzoyl peroxide creams?

No. The supplied claims require encapsulated or microencapsulated benzoyl peroxide and additional rosacea, age, dosing and efficacy limitations.

Can a generic avoid the patent by labeling the product only for acne?

Potentially. An acne-only label may avoid the claimed rosacea regimen, but the sponsor must evaluate induced-infringement risk, actual marketing conduct and other patents in the family.

Does the patent cover treatment of patients younger than 65?

The supplied claims require subjects aged 65 years and older. Treatment of younger patients does not literally satisfy that age limitation.

Are the IGA thresholds product characteristics?

They are claim limitations tied to treatment outcomes in a group of patients. They are not simply physical characteristics of the cream and may require clinical or real-world evidence to establish infringement.

Does FDA approval prove infringement of US 10,933,046?

No. FDA approval establishes regulatory authorization for the approved product and indication. Patent infringement depends on whether the accused product and use satisfy every limitation of an asserted claim.

References

  1. U.S. Food and Drug Administration. (2022). Epsolay (benzoyl peroxide) cream, 5%: Prescribing information.
  2. U.S. Patent and Trademark Office. (2022). United States Patent No. 10,933,046.
  3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
  4. U.S. Code. (2023). 21 U.S.C. § 355(j): Abbreviated applications for new drugs.
  5. U.S. Code. (2023). 35 U.S.C. §§ 101, 102, 103, 112 and 154.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,933,046

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mayne Pharma EPSOLAY benzoyl peroxide CREAM;TOPICAL 214510-001 Apr 22, 2022 RX Yes Yes 10,933,046 ⤷  Start Trial Y TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 65 YEARS OF AGE AND OLDER ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.